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ABSTRACT
Objective Early treatment following a ﬁrst clinical
demyelinating event (FCDE) delays further disease
activity in patients with multiple sclerosis (MS). This
study determined the effects of early versus delayed
treatment (DT) with subcutaneous interferon (sc IFN) β-
1a 44 μg in patients with an FCDE up to 60 months
postrandomisation.
Methods Patients who completed the 24-month
double-blind REFLEX (REbif FLEXible dosing in early MS)
study entered an extension (REFLEXION, REbif FLEXible
dosing in early MS extensION): patients initially
randomised to sc IFN β-1a and not reaching clinically
deﬁnite MS (clinically deﬁnite MS, CDMS (second attack
or sustained Expanded Disability Status Scale (EDSS)
score increase)) continued original treatment (three times
weekly (tiw) or once weekly (qw)); placebo patients
switched to tiw (DT); patients with CDMS switched to
tiw. Clinical, MRI and adverse event data up to month
60 are reported.
Results 402/517 (77.8%) REFLEX patients entered
REFLEXION (DT, n=133; tiw, n=127; qw, n=142). At
month 60, cumulative probability of CDMS was: DT
44.6%; qw 40.7% (nominal p=0.084 vs DT); tiw
39.2% (nominal p=0.032 vs DT). Cumulative probability
of McDonald MS conversion (CDMS or new MRI activity)
at month 60 was also reduced for tiw versus DT
(nominal p<0.001). At month 60, mean cumulative
numbers of new T2, gadolinium-enhancing and T1
hypointense lesions were lower with sc IFN β-1a qw
(nominal p<0.05) and tiw versus DT (nominal p<0.001);
T2 and T1 hypointense lesion volume change was lower
for sc IFN β-1a tiw versus DT (nominal p<0.01).
Treatment was well tolerated; fewer patients receiving
tiw versus qw were positive for neutralising or binding
antibodies.
Conclusions Over 5 years in patients presenting with
an FCDE, early sc IFN β-1a tiw administration versus DT
prolonged time to CDMS and McDonald MS, and
reduced overall MRI activity.
Trial registration number NCT00813709; Results.
INTRODUCTION
The initial manifestation of multiple sclerosis (MS)
is often a ﬁrst clinical demyelinating event (FCDE),
also known as a clinically isolated syndrome (CIS),
which frequently affects the optic nerve, brainstem
or spinal cord.1 Clinical trials performed in CIS
have shown that between 38% and 45% of
untreated patients convert to clinically deﬁnite MS
(CDMS (a new attack or sustained increase in
Expanded Disability Status Scale (EDSS) score))
within 2 years.2–4
The diagnosis of CDMS is made after the exclu-
sion of other differential diagnoses and the occur-
rence of either a second clinical attack at least
1 month after the ﬁrst, based on evidence of
involvement of more than one area in the central
nervous system, or evidence of disease progression,
as noted by a sustained increase in EDSS score.5
The McDonald criteria, ﬁrst introduced in 2001,6
and revised in 20057 and 2010,8 take into account
lesions on MRIs, allowing earlier diagnosis even
before a second clinical attack occurs.8
Treatment recommendations advise that patients
should be treated as early as possible after an
FCDE,9 and previous studies have shown that early
treatment (ET) with interferon (IFN) β, glatiramer
acetate, oral teriﬂunomide or oral cladribine has
beneﬁcial effects in patients with an FCDE for
reducing the risk of developing MS.3 4 10–14 The
REFLEX (REbif FLEXible dosing in early MS)
phase III study2 demonstrated that ET with IFN
β-1a 44 μg, initiated after the FCDE and adminis-
tered subcutaneously (sc) three times weekly (tiw)
or once weekly (qw) over 24 months, delayed con-
version to McDonald MS (2005 criteria)7 and
CDMS compared with placebo.2 More frequent
treatment (tiw vs qw) prolonged time to McDonald
MS conversion. REFLEXION (REbif FLEXible
dosing in early MS extensION), a preplanned
extension of the REFLEX study, was designed to
evaluate the beneﬁts of more frequent and early
dosing versus delayed treatment (DT) on disease
course over a prolonged period. It compared the
efﬁcacy, in terms of progression to CDMS and
McDonald MS, proportion of patients remaining
relapse-free, EDSS progression and MRI outcomes,
safety and immunogenicity of ET with sc IFN β-1a
44 μg (tiw or qw) versus DT over 60 months since
randomisation in REFLEX. The results of an inte-
grated analysis from REFLEX and REFLEXION
are presented here.
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METHODS
REFLEXION (NCT00813709) was a multicentre, double-blind,
controlled extension of the phase III REFLEX study
(NCT00404352),2 conducted at 70 centres in 24 countries
(Argentina, Austria, Belgium, Bulgaria, Canada, Croatia, the
Czech Republic, Estonia, Finland, France, Germany, Greece,
Israel, Italy, Latvia, Lebanon, Morocco, Poland, Portugal,
Romania, Russia, Serbia, Slovakia and Spain) in accordance with
the International Conference on Harmonisation guidelines for
Good Clinical Practice, applicable local regulations and the
Declaration of Helsinki. All participants provided written
informed consent to continue follow-up in REFLEXION.
REFLEX was initiated on 16 November 2006 (ﬁrst patient ﬁrst
visit), and REFLEXION on 22 December 2008, with the last
patient completing the month 60 visit on 30 August 2013.
Patients and procedures
Inclusion/exclusion criteria and the randomisation procedure for
REFLEX have been described.2 Brieﬂy, REFLEX recruited
patients aged 18–50 years who had an EDSS score of ≤5.0, a
single clinical event suggestive of MS within 60 days of study
entry, and ≥2 clinically silent lesions ≥3 mm on T2-weighted
brain MRI (at least one of which was ovoid, periventricular or
infratentorial). Patients were randomised (1:1:1) to the serum-
free formulation of sc IFN β-1a 44 μg tiw or qw (plus placebo
twice weekly for blinding), or placebo, for 24 months or until
CDMS (deﬁned by a second attack or a sustained increase in
EDSS score of ≥1.5 points). On conversion to CDMS, patients
from any treatment arm were switched to open-label sc IFN
β-1a 44 μg tiw without unblinding of the initial randomisation.
Exclusion criteria included: any disease other than MS that
could better explain the patient’s signs and symptoms; a
primary progressive course of MS; a medical objection to con-
tinuing in the study (laboratory abnormalities and clinically sig-
niﬁcant liver, renal or bone marrow dysfunction).
All patients who completed the 24-month period of REFLEX
were eligible for the REFLEXION extension. Patients initially
randomised to sc IFN β-1a 44 μg tiw or qw who had not
converted to CDMS continued their original dosing regimen
(ﬁgure 1). Patients originally receiving placebo who had not
converted to CDMS were switched to sc IFN β-1a 44 μg tiw,
forming the REFLEXION DT group; patients who converted to
CDMS during REFLEX or REFLEXION received open-label sc
IFN β-1a 44 μg tiw from then on. Patients who completed
REFLEX but were not on treatment (ie, withdrew from treat-
ment but not from the study) could restart treatment at entry to
REFLEXION, and received double-blind IFN β-1a (qw or tiw) if
they had not converted to CDMS (those who had converted to
CDMS restarted with open-label IFN β-1a tiw). Blinding to the
initial treatment assignment in REFLEX was maintained in all
cases. To maintain initial blinding, all patients who had not con-
verted to CDMS entered a 4-week retitration phase, whereby
they received 20% of the full dose (8.8 μg qw or tiw) for the ﬁrst
2 weeks and 50% (22 μg qw or tiw) for the following 2 weeks.
Other procedures were as previously described.2
Study assessments
In REFLEX, efﬁcacy and safety data were collected every
3 months up to conversion and then every 6 months. In
REFLEXION, EDSS scores and CDMS assessments were
recorded at extension baseline (month 24) and every 6 months
thereafter. MRIs were performed every 3 months during
REFLEX, at extension baseline and then yearly at months 36,
48 and 60 (or at the end-of-treatment visit in patients who dis-
continued). MRIs were analysed centrally at the VU University
Medical Center, Amsterdam, the Netherlands, to ensure homo-
geneity, as described previously.15 Adverse events (AEs) were
monitored at months 25 and 27 and then every 3 months to the
study end.
Study end points
The primary end point was time to CDMS conversion (deﬁned
in REFLEX)2 from ﬁrst randomisation to month 36; time to
CDMS to month 60 was a secondary end point. Additional sec-
ondary end points included (months 36 and 60): time to con-
version to McDonald MS (2005 criteria, deﬁned previously);2 7
proportion of patients remaining relapse-free; time to conﬁrmed
EDSS progression (increase of ≥1.0 point, conﬁrmed during a
visit 6 months later) and EDSS change from baseline; mean
total T2 lesions and mean number of new T2, T1 hypointense
and gadolinium-enhancing (Gd+) lesions/patient/scan; change
from baseline in volume of T2, T1 hypointense and Gd+ lesion
volume; percentage brain volume change at months 36 and 60
vs baseline; development of neutralising and binding antibodies
(nAbs; bAbs, respectively) to IFN β-1a over time (samples for
immunogenicity assessments were taken at 6-month intervals
until conversion to CDMS); and incidence of AEs, serious AEs
(SAEs) and AEs leading to treatment discontinuation.
Figure 1 REFLEX and REFLEXION
study design. Short arrows indicate
conversion to CDMS and the
consequent switch to open-label
treatment, which could happen at any
time throughout the study. CDMS,
clinically deﬁnite multiple sclerosis;
IFN, interferon; MS, multiple sclerosis;
qw, once weekly; REFLEX, REbif
FLEXible dosing in early MS;
REFLEXION, REbif FLEXible dosing in
early MS extension; sc, subcutaneous;
tiw, three times weekly.
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Statistical analyses
Study populations included the integrated intent-to-treat (ITT)
population consisting of all patients randomised in REFLEX,
including those who did not enrol in REFLEXION; the inte-
grated double-blind safety population, which included all
patients who had received at least one dose of double-blind
treatment in REFLEX; the REFLEXION ITT population, which
included all patients enrolled in REFLEXION; the
REFLEXION double-blind safety population, which included
all patients who had received at least one dose of double-blind
treatment in REFLEXION.
For the primary end point, statistical testing was performed
comparing the three treatment groups pairwise in a hierarchical
order to control for family-wise type I error rate (tiw ET and
DT; then qw ET and DT; then tiw ET and qw ET). Probabilities
of CDMS conversion, McDonald MS conversion and EDSS pro-
gression over time were determined for each treatment group in
the form of cumulative incidence curves estimated using the
non-parametric Kaplan-Meier method; pairwise comparison of
the treatment groups and estimation of treatment effect was per-
formed as described previously.2
For MRI lesion number end points, pairwise treatment differ-
ences were analysed using a negative binomial regression model,
with treatment and randomisation stratiﬁcation factors as covari-
ates. The number of scans was used as an offset variable. An
approximate χ2 test based on Wald statistics was used for the
pairwise comparison of treatment groups. For MRI volume end
points, change from baseline to month 36 was analysed using a
non-parametric analysis of covariance (ANCOVA) adjusted for
treatment, randomisation stratiﬁcation factors and baseline value
as covariates. Estimates of size in treatment differences were
obtained using a parametric ANCOVA. Month 60 statistical
analyses were exploratory; therefore, all p values were nominal,
with no formal hypothesis testing for month 60 analysis and no
multiplicity adjustment for the p value (p values <0.05 are
reported).
RESULTS
In total, 402/517 (77.8%) patients randomised in REFLEX con-
tinued in REFLEXION: 127/171 originally randomised to sc
IFN β-1a 44 mg tiw; 142/175 originally randomised to sc IFN
β-1a 44 μg qw; and 133/171 in the DT arm (originally rando-
mised to placebo); 371/402 (92.3%) completed the month 60
visit. Patient disposition for the integrated ITT population in
the two studies is presented in ﬁgure 2. The baseline demo-
graphics and clinical characteristics of patients (at the time of
randomisation in REFLEX) were comparable across treatment
groups (table 1). Those patients who converted to CDMS
during REFLEX and received open-label treatment were similar
with respect to age, sex, race and history of FCDE (see online
supplementary table S1).
The baseline characteristics of those who did not continue in
REFLEXION were similar to those of the overall population at
the start of REFLEX, although a higher proportion of women
and higher MRI activity was apparent in those who did not con-
tinue in REFLEXION (see online supplementary table S1).
There was no indication that clinical outcomes in REFLEX
(conversion to CDMS or McDonald MS) were associated with
patients not continuing to REFLEXION, indicating no bias in
the REFLEXION population, as shown by disease characteristics
in those patients who, at the end of REFLEX, did or did not
continue to REFLEXION (see online supplementary table S2).
In the REFLEXION double-blind safety population com-
prising 300 patients (tiw, n=99; qw, n=117; DT, n=84),
Figure 2 Patient disposition in
REFLEX and REFLEXION (integrated
intent-to-treat population). IFN,
interferon; MS, multiple sclerosis; qw,
once weekly; REFLEX, REbif FLEXible
dosing in early MS; REFLEXION, REbif
FLEXible dosing in early MS extension;
sc, subcutaneous; tiw, three times
weekly.
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197/295 (66.8%) completed double-blind treatment (and 5
patients did not receive double-blind treatment during
REFLEXION (stopped treatment during REFLEX but were
enrolled in REFLEXION)). Of those who discontinued
prematurely (45/295 (15.3%)), more patients discontinued
from DT (21 (25.3%)) than from tiw (12 (12.2%)) or qw
(12 (10.5%)). Reasons for discontinuation were treatment-
emergent AEs (TEAEs; 9 patients (20.0%)), lost to follow-up
(7 (15.6%)) and other reasons (29 (64.4%)). Median compli-
ance (proportion of scheduled doses administered) in the
safety population (months 24–60) was >99% for all three
treatment groups.
Time to CDMS conversion from baseline to study end in the
integrated ITT population is shown in ﬁgure 3. At month 36
(primary end point), there were lower proportions of patients
who had converted to CDMS by month 36 with tiw and qw
than with DT (25.1%, 25.7% and 38.6%, respectively), and
lower cumulative probability of CDMS conversion (27.1%,
27.6% and 41.3%, respectively). The risk of CDMS conversion
was signiﬁcantly reduced for patients receiving ET (tiw or qw)
compared with DT (p≤0.006 for both tiw and qw vs DT), with
no signiﬁcant difference between the ET groups (p=0.941;
table 2). Results for the month 60 analysis also showed longer
times to CDMS conversion in both ET groups compared with
Table 1 Baseline demographics and disease characteristics of the REFLEXION intent-to-treat population (at the time of randomisation to
REFLEX)
Characteristic
sc IFN β-1a tiw
n=127 (74.3% of REFLEX)
sc IFN β-1a qw
n=142 (81.1% of REFLEX)
DT
n=133 (77.8% of REFLEX)
Overall
n=402 (77.8% of REFLEX)
Age, years 31.8 (8.6) 31.4 (8.2) 31.0 (8.2) 31.4 (8.3)
Women, n (%) 78 (61.4) 88 (62.0) 82 (61.7) 248 (61.7)
EDSS score 1.5 (0–4.0)* 1.5 (0–3.5) 1.5 (0–3.5) 1.5 (0–4.0)*
Time since FCDE, days 57.6 (3.83) 57.7 (3.40) 57.8 (4.04) 57.7 (3.75)
Classification of FCDE as monofocal,† n (%) 66 (52.0) 76 (53.5) 72 (54.1) 214 (53.2)
Steroid use at FCDE, n (%) 90 (70.9) 99 (69.7) 95 (71.4) 284 (70.6)
Presence of ≥1 T1 Gd+ lesion, n (%) 48 (37.8) 62 (43.7) 52 (39.1) 162 (40.3)
T1 Gd+ lesion number 1.2 (2.5) 1.5 (3.4) 1.0 (1.8) 1.2 (2.7)
T1 Gd+ lesion volume, mm3 147.94 (430.64) 169.20 (384.88) 142.93 (453.35) 153.79 (422.07)
T1 hypointense lesions 6.4 (7.3) 6.1 (7.6) 5.6 (8.1) 6.0 (7.7)
T1 hypointense lesion volume, mm3 787.05 (1163.61) 806.48 (1344.18) 705.40 (1115.41) 766.90 (1213.36)
T2 lesion number 22.6 (17.4) 24.3 (21.8) 20.7 (19.7) 22.6 (19.8)
≥9 T2 lesions, n (%) 100 (78.7) 104 (73.2) 95 (71.4) 299 (74.4)
T2 lesion volume, mm3 3312.00 (3370.44) 3798.88 (4490.66) 3296.99 (3937.93) 3479.02 (3977.55)
Normalised brain volume, cm3 1533.12 (76.83) 1532.72 (65.95) 1541.25 (64.95) 1535.65 (69.21)
Data are presented as mean (SD) or median (range), unless indicated otherwise.
*Data missing for one patient.
†As classified by the adjudication committee.
DT, delayed treatment; EDSS, Expanded Disability Status Scale; FCDE, first clinical demyelinating event; Gd+, gadolinium-enhancing; IFN, interferon; MS, multiple sclerosis; qw, once
weekly; REFLEX, REbif FLEXible dosing in early MS; REFLEXION, REbif FLEXible dosing in early MS extensION; sc, subcutaneously; tiw, three times weekly.
Figure 3 Time to CDMS conversion during the double-blind period: Kaplan-Meier cumulative incidence curves (integrated intent-to-treat
population, N=517). Arrows indicate MRI assessments. CDMS, clinically deﬁnite multiple sclerosis; IFN, interferon; qw, once weekly; sc,
subcutaneously; tiw, three times weekly.
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DT. The proportion of patients who converted to CDMS had
increased at month 60, although it was still lower in those
receiving tiw and qw ET than with DT (32.2%, 36.0% and
40.4%). Similarly, cumulative probability of conversion was
lower with tiw and qw ET than with DT (39.2%, 40.7% and
44.6%), with a relative risk reduction of 31.7% for tiw versus
DT (nominal p=0.032; ﬁgure 3; table 2). A preplanned explora-
tory analysis of time to CDMS evaluated possible treatment
effects after adjusting for the randomisation stratiﬁcation
factors. This analysis showed that the presence of Gd+ lesions
at screening was a factor that may contribute to the effect of
treatment (HR point estimate (95% CI) 1.457 (1.017 to 2.086);
nominal p=0.040).
Time to McDonald MS conversion from baseline to study
end in the integrated ITT population is shown in ﬁgure 4. A
higher percentage of DT patients had converted to
McDonald MS compared with the ET groups at most of the
assessments. At month 36, the cumulative probability of con-
version to McDonald MS was signiﬁcantly lower with both sc
IFN β-1a dosing regimens than DT (tiw 66.8% (nominal
p<0.001); qw 79.1% (nominal p=0.009); DT 86.5%) and
remained lower with tiw at month 60 (79.2%) versus DT
(86.5%), but not for qw (89.5%). sc IFN β-1a tiw was asso-
ciated with a relative risk reduction of time to conversion to
McDonald MS of 30.8% versus qw at month 60 (nominal
p=0.005; table 2).
Minimal differences were seen for numbers with conﬁrmed
EDSS progression between groups (see online supplementary
table S3). Mean EDSS scores from baseline are shown in online
supplementary table S3; the mean change in EDSS score from
baseline to month 60 was −0.05, −0.03 and −0.16 for tiw, qw
and DT, respectively.
Table 2 Effects of treatment on conversion to CDMS and McDonald MS (integrated analysis, intent-to-treat population, double-blind period)
sc IFN β-1a tiw
n=171
sc IFN β-1a qw
n=175
Delayed treatment
n=171
Conversion to CDMS
Month 36
Patients converting (%) 25.1 25.7 38.6
Cumulative probability of CDMS (%) 27.1 27.6 41.3
HR (95% CI) vs DT 0.555 (0.38; 0.82) 0.573 (0.39; 0.84) –
Relative risk reduction vs DT (%) 44.5 42.7 –
p Value 0.002 0.006 –
HR (95% CI) vs qw 0.993 (0.65; 1.51) – –
Relative risk reduction vs qw (%) 0.7 – –
p Value 0.941 – –
Month 60
Patients converting (%) 32.2 36.0 40.4
Cumulative probability of CDMS (%) 39.2 40.7 44.6
HR (95% CI) vs DT 0.683 (0.48; 0.98) 0.752 (0.53; 1.06) –
Relative risk reduction vs DT (%) 31.7 24.8 –
Nominal p value 0.032 0.084 –
HR (95% CI) vs qw 0.940 (0.65; 1.35) – –
Relative risk reduction vs qw (%) 16.0 – –
Nominal p value 0.852 – –
Conversion to McDonald MS
Month 36
Patients converting (%) 66.7 76.0 84.2
Cumulative probability of McDonald MS (%) 66.8 79.1 86.5
HR (95% CI) vs DT 0.508 (0.40; 0.65) 0.698 (0.55; 0.89) –
Relative risk reduction vs DT (%) 49.2 30.2 –
Nominal p value <0.001 0.009 –
HR (95% CI) vs qw 0.722 (0.56; 0.93) – –
Relative risk reduction vs qw (%) 27.8 – –
Nominal p value 0.024 – –
Month 60
Patients converting (%) 72.5 82.9 84.2
Cumulative probability of McDonald MS (%) 79.2 89.5 86.5
HR (95% CI) vs DT 0.546 (0.43; 0.70) 0.759 (0.60; 0.96) –
Relative risk reduction vs DT (%) 45.4 24.1 –
Nominal p value <0.001 0.040 –
HR (95% CI) vs qw 0.692 (0.54; 0.88) – –
Relative risk reduction vs qw (%) 30.8 – –
Nominal p value 0.005 – –
Cumulative probability: Kaplan-Meier estimate of the cumulative probability of CDMS or McDonald MS; HR: multivariate Cox proportional hazards model with treatment and
randomisation stratification factors as covariates; p value: two-sided log-rank test, stratified for randomisation stratification factors. Month 60 statistical analyses were exploratory;
therefore, all p values for this time point were nominal (p values <0.05 are reported).
CDMS, clinically definite multiple sclerosis; DT, delayed treatment; IFN, interferon; MS, multiple sclerosis; qw, once weekly; sc, subcutaneously; tiw, three times weekly.
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Table 3 summarises the effect of treatment on MRI end
points. Treatment with tiw was associated with a lower adjusted
mean total number of T2 lesions than DTat month 36 (nominal
p=0.031) and month 60 (nominal p=0.029). At both time
points, both tiw and qw regimens were associated with lower
numbers of new T2 lesions (months 36 and 60, nominal
p<0.001), new Gd+ lesions (months 36 and 60, nominal
p<0.001) and new T1 hypointense lesions (Months 36 and 60,
nominal p<0.05). The mean number of lesions per patient per
scan by year is shown in online supplementary table S4.
In all treatment groups, there was a reduction in mean T2
lesion volume and an increase in T1 hypointense lesion volume
from baseline to the last observed value (LOV) during the study
(ﬁgure 5). Patients in the tiw ET group had greater mean reduc-
tions in T2 lesion volume than patients in the qw ET group
(month 36, nominal p=0.009; month 60, nominal p=0.013)
and patients in the DT group (months 36 and 60, nominal
p<0.001); there were no differences between the qw and DT
groups. In contrast, T1 hypointense lesion volume increased in
all groups, but the increase was consistently less in only the tiw
group compared with the DT group (months 36 and 60,
nominal p=0.007; ﬁgure 5).
There were no notable differences between groups for the
mean change in Gd+ lesion volume from study baseline (month
0) to month 36 LOV and month 60 LOV. There were no differ-
ences between ETand DT in mean percentage change from base-
line in brain volume. However, qw treatment was associated with
less brain volume reduction than tiw treatment (months 0–36,
−0.889% vs −1.114%, nominal p=0.026; months 0–60,
−1.409% vs −1.777%, nominal p=0.032). Brain volume
reduction during the REFLEXION study period (using month
24 as baseline) was more pronounced at each time point in the
DT group than in either ET group (see online supplementary
table S5).
In the integrated double-blind safety population, the propor-
tion of patients who were nAb-positive (≥20 neutralising units/
mL) at any time during the 60-month study period was 16.0%
(27/169) for tiw, 21.4% (36/168) for qw and 14.8% (25/169)
for DT. During the ﬁrst 18 months of treatment (months 24–42
for DT), the proportion of nAb-positive patients increased
across all groups, and then remained relatively constant and
similar (see online supplementary ﬁgure S1). The proportion of
patients bAb-positive was highest in the tiw group after
6 months of treatment; with DT, the proportion was highest at
month 30 (reﬂecting the ﬁrst 6 months after patients switched
to tiw), before declining over time to month 60. The proportion
of patients bAb-positive remained relatively constant for the qw
group (see online supplementary ﬁgure S2).
Table 4 presents TEAEs reported between months 24 and 60
(REFLEXION double-blind safety population). Approximately
83% of patients within each treatment group experienced at
least one TEAE, with more DT patients reporting drug-related
TEAEs versus the ET groups. The percentage of patients with
any AE of severe intensity, SAEs or an AE that led to discontinu-
ation was comparable between the three treatment groups. Only
six TEAEs occurred in ≥10% of patients in any group:
inﬂuenza-like illness, headache, upper respiratory tract infection,
nasopharyngitis, injection-site erythema and leucopenia. A
higher percentage of patients in the DT group had at least one
prespeciﬁed TEAE (MeDRA preferred term), with more patients
experiencing inﬂuenza-like syndrome, injection-site reactions
and hypersensitivity reactions than in the ET groups.
Prespeciﬁed AEs were transient and resolved over time.
DISCUSSION
REFLEXION, a preplanned extension of the phase III REFLEX
study,2 was designed to evaluate how two different dosing fre-
quencies of sc IFN β-1a 44 μg initiated at the time of an FCDE
inﬂuence later disease course compared with DT. The results
from REFLEXION are consistent with the ﬁndings from
REFLEX and further suggest that, over 5 years, initiating ET
with sc IFN β-1a within 60 days of an FCDE signiﬁcantly
Figure 4 Time to conversion to McDonald MS during the double-blind period: Kaplan-Meier cumulative incidence curves (integrated intent-to-treat
population, N=517). Arrows indicate MRI assessments. IFN, interferon; MS, multiple sclerosis; qw, once weekly; sc, subcutaneously; tiw, three times
weekly.
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prolonged time to conversion to MS compared with a treatment
delay of up to 2 years.
Furthermore, both in REFLEX and REFLEXION, there was a
difference between the two dose frequencies of sc IFN β-1a in
the time to McDonald MS, in favour of tiw dosing. This differ-
ence was accounted for by a difference in MRI outcome
between the two groups. Indeed, by systematically incorporating
MRI lesions as surrogates of clinical events, and as lesions occur
more frequently than relapses,16 17 the McDonald criteria
provide a sensitive tool to measure disease activity and anti-
inﬂammatory drug effects.6–8 No difference between the two
groups was observed for the time to CDMS.
Analysis of MRI outcomes in this study also showed beneﬁts
with ET, as previously suggested from the ﬁndings of the MRI ana-
lysis of REFLEX.15 ETwas associated with marked reductions in
new lesions compared with DT over 5 years. Although the mean
number of lesions per patient per scan by year shows fewer lesions
in the DT group than the tiw and qw groups, patients in the DT
group may have less active disease (patients converting to CDMS
would already have been switched to tiw and remaining patients
received tiw at start of REFLEXION). Furthermore, tiw was asso-
ciated with greater reductions in T2 lesion volume compared with
qw, conﬁrming the short-term dose effect previously observed in
REFLEX. It is possible that the reductions in T2 lesion volume
observed were related to patients with more active disease being
lost to follow-up, skewing the patient population included in these
analyses. Further analysis of the MRI data is warranted, as previ-
ous studies have suggested a role for lesions at the time of an
FCDE in predicting future disease activity.18 Analyses of the
BENEFIT study19 and the ETOMS study20 showed that the pres-
ence of Gd+ lesions or ≥9 T2 lesions at baseline led to higher per-
centages of patients converting to CDMS. IFN β has been shown
to have a robust treatment effect in patients with CIS, including
those with greater MRI disease burden or activity.21–23 The
dose effect observed in REFLEX and conﬁrmed in REFLEXION
is consistent with the ﬁnding that higher dose sc IFN β-1a (44 μg
tiw) is associated with better MRI outcomes than lower dose
(22 μg tiw)24 or less frequent intramuscular IFN β-1a.25
Changes in brain volume did not differ between groups but
should be interpreted with caution; brain volume changes
during the ﬁrst year of treatment, especially with high frequency
DT sc IFN β-1a, may have a stronger anti-inﬂammatory effect,
causing accelerated, non-tissue-related brain volume decline
(pseudoatrophy).26 27 This phenomenon was observed in
patients switching in other extension studies.11 28
These results from REFLEXION add to a small but growing
number of trials, which suggest that ETof an FCDE with IFN β is
associated with improved long-term clinical, paraclinical and
MRI outcomes to at least 5 years.4 11 28–31 In the 5-year active
treatment extension of the phase 3 BENEFIT trial, ETwith IFN
Table 3 Effects of treatment on MRI end points (integrated analysis, intent-to-treat population, double-blind period)
sc IFN β-1a tiw n=171 sc IFN β-1a qw n=175
Delayed treatment
n=171
T2 lesions, mean (SE)
Month 36 21.16 (1.44) 24.61 (1.62) 25.79 (1.73)
Rate ratio (95% CI) vs DT 0.82 (0.69; 0.98) 0.95 (0.80; 1.14) –
Nominal p=0.031 Nominal p=0.606
Month 60 21.46 (1.45) 24.95 (1.62) 26.19 (1.74)
Rate ratio (95% CI) vs DT 0.82 (0.69; 0.98) 0.95 (0.80; 1.14) –
Nominal p=0.029 Nominal p=0.591
New T2 lesions, mean (SE)
Month 36 0.47 (0.06) 0.61 (0.07) 1.14 (0.13)
Rate ratio (95% CI) vs DT 0.41 (0.30; 0.56) 0.53 (0.39; 0.73) –
Nominal p<0.001 Nominal p<0.001
Month 60 0.55 (0.07) 0.66 (0.08) 1.11 (0.13)
Rate ratio (95% CI) vs DT 0.49 (0.36; 0.68) 0.59 (0.43; 0.81) –
Nominal p<0.001 Nominal p<0.001
New Gd+ lesions, mean (SE)
Month 36 0.14 (0.03) 0.29 (0.05) 0.74 (0.13)
Rate ratio (95% CI) vs DT 0.18 (0.11; 0.30) 0.39 (0.24; 0.63) –
Nominal p<0.001 Nominal p<0.001
Month 60 0.16 (0.03) 0.28 (0.05) 0.69 (0.13)
Rate ratio (95% CI) vs DT 0.23 (0.14; 0.38) 0.41 (0.25; 0.67) –
Nominal p<0.001 Nominal p<0.001
New T1 hypointense lesions, mean (SE)
Month 36 0.33 (0.05) 0.47 (0.06) 0.73 (0.09)
Rate ratio (95% CI) vs DT 0.45 (0.32; 0.65) 0.64 (0.45; 0.91) –
Nominal p<0.001 Nominal p=0.012
Month 60 0.35 (0.05) 0.49 (0.06) 0.70 (0.09)
Rate ratio (95% CI) vs DT 0.50 (0.35; 0.70) 0.70 (0.50; 0.97) –
Nominal p<0.001 Nominal p=0.035
Data are per patient per scan unless stated otherwise. The negative binomial regression model is corrected for overdispersion with treatment and randomisation stratification factors as
covariates and number of scans as an offset variable. Month 60 statistical analyses were exploratory; therefore, all p values for this time point were nominal (p values <0.05 are
reported).
DT, delayed treatment; Gd+, gadolinium-enhancing; IFN, interferon; qw, once weekly; sc, subcutaneous; tiw, three times weekly.
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β-1b every other day reduced the risk of CDMS by 37%,
although DT by up to 2 years did not affect long-term conﬁrmed
disability progression, as measured by the EDSS.28 In a 10-year
follow-up of the open-label CHAMPIONS study (an extension
of the CHAMPS trial), ETwith intramuscular IFN β-1a reduced
the rate of CDMS; however, there was no differential effect on
disability, MRI T2-weighted lesions or the proportion of patients
developing progressive disease.30 31 Further analysis identiﬁed
patients with low T2 lesion counts as having a signiﬁcantly less
severe disease course.32 It is important to consider that
CHAMPS enrolled primarily patients with monofocal disease
presentation (some were later redeﬁned as multifocal), whereas
patients in BENEFITand REFLEX could have had monofocal or
multifocal disease onset at the study start.33
The absence of a continuation placebo group, as patients ini-
tially randomised to placebo who had not converted to CDMS
were switched to tiw treatment for REFLEXION, is a limitation
of this study. Patients randomised to qw treatment were also
switched to tiw on CDMS, limiting the possibility to observe
differences between the two active arms, and resulting in a bias
towards patients in the tiw arm with potentially more active
disease. Furthermore, patients in the DT group were biased
towards less active disease as they had not yet converted to
CDMS at the start of REFLEXION. Nevertheless, a treatment
effect is still evident on MRI, but it could not be determined
that tiw dosing was superior to qw dosing for delaying conver-
sion to CDMS. However, tiw dosing consistently reduced MRI
activity to a greater extent than was seen with qw dosing.
Additionally, tiw dosing led to fewer TEAEs, particularly
inﬂuenza-like symptoms and reduced immunogenicity. While
REFLEX and REFLEXION used the 2005 McDonald criteria,7
the most recent criteria are McDonald 2010,8 meaning that
some patients would now be diagnosed with MS and excluded
from the study. However, a subgroup analysis of REFLEX sug-
gests that had the McDonald 2010 criteria been available at the
time of the study design, the main ﬁndings from REFLEX
would not have been affected.34
Immunogenicity and safety data were consistent with those
reported in REFLEX,2 and in agreement with the well-
established safety proﬁle of sc IFN β-1a, involving 20 years of
follow-up data.24 35–37 The higher proportion of patients with
TEAEs in the DT group most likely reﬂects the typical time
course of TEAEs shortly after starting IFN β treatment to which
the majority of patients can adjust, and to which those in the
REFLEX tiw and qw groups had already adjusted.
The results of REFLEXION extend the clinical and MRI ﬁnd-
ings of the REFLEX study and show that, over 5 years in
patients with an FCDE, early initiation of treatment with sc IFN
Figure 5 Change from baseline to LOV in mean T2 lesion volume at (A) month 36 and (B) month 60, and mean T1 hypointense lesion volume at
(C) month 36 and (D) month 60 by original treatment group (integrated intent-to-treat population, N=517). Data are unadjusted raw means. Point
estimate (95% CI) estimated using a parametric ANCOVA model with treatment, randomisation stratiﬁcation factors and baseline value as
covariates. p Values obtained using a non-parametric ANCOVA (ANCOVA on ranked data) with treatment, randomisation stratiﬁcation factors and
baseline value as covariates. ANCOVA, analysis of covariance; DT, delayed treatment; IFN, interferon; LOV, last observed value; qw, once weekly; sc,
subcutaneous; tiw, three times weekly.
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β-1a prolonged time to CDMS and McDonald MS, and reduced
MRI activity compared with DT. This further supports the early
initiation of treatment with sc IFN β-1a at the time of the
FCDE, with patients receiving ET beneﬁting from improved
outcomes.
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